Long-Term Safety

4 · 20 / page

Ask MedXY AI

Latest news

Tag

CardiologyAficamtenCardiac Myosin Inhibitor

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study

By MedXY|Jun 28, 2026

The FOREST-HCM long-term study confirms aficamten’s efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up

Diabetes & Endocrinology

Long-Term Safety

Latest news

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study

Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up

Long-Term Success of Satralizumab in Managing NMOSD: Insights from the SAkuraMoon Study

Long-Term Safety of Antenatal Corticosteroids: Insights from the 50-Year Follow-Up of the Auckland Steroid Trial